The place of targeted treatments: Receptor tyrosine kinase inhibitors;Place des thérapeutiques ciblées: Les inhibiteurs des récepteurs tyrosine kinases

Revue de Pneumologie Clinique

Volumn 60, Issue 5 II, 2004, Pages

  Brechot J M ^a  

^a AVICENNE HOSPITAL   (France)

Author keywords

Antiangiogenic therapy; Epidermal growth factor inhibitor; Lung cancer; Targeted therapy

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GEFITINIB; GEMCITABINE; IMATINIB; MEMBRANE RECEPTOR; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; TRASTUZUMAB; TYROSINE KINASE RECEPTOR INHIBITOR; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN E; VASCULOTROPIN RECEPTOR;

ACNE; ANTIGEN BINDING; BLOOD TOXICITY; CANCER CELL; CELL SPECIFICITY; CONFERENCE PAPER; DIARRHEA; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; ENZYME INHIBITION; HUMAN; INTERSTITIAL LUNG DISEASE; LIGAND BINDING; LUNG CANCER; RECEPTOR BINDING; RECEPTOR BLOCKING; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN DISEASE;

HUMANS; LUNG NEOPLASMS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, ERBB-2; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 12244312807     PISSN: 07618417     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (10)

1. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000;103:211-25.
2. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinases, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-58.
3. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefinitib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003;21:2237-46.
4. Giacconne G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial- INTACT 1. J Clin Oncol 2004;22:777-84.
5. Herbst RS, Giacconne G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial- INTACT 2. J Clin Oncol 2004;22:785-94.
6. Perez-Soler R, Chachoua A, Huberman M, et al. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (OSI-774), following platinum-based chemotherapy, in patients with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2001;20:310a(abst. 1235).
7. Gatzmeier U, Groth G, Butts C, et al. Randomised phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol 2004;15:19-27.
8. De Vore R, Fehrenbacher L, Herbst CJ, et al. A randomized phase II trial comparing rhuMab VEGF plus carboplatin/paclitaxel (CP) to CP alone in patients with stage HIB-IV non small cell lung cancer. Proc Am Soc Clin Oncol 2000;19:458a.
9. Jain RK, Padera TP. Prevention and treatment of lymphatic metastasis by lymphangiogenic therapy. J Natl Cancer Inst 2002;94:785-7.
10. Bunn PA, Sheperd FA, Sandler A, et al. Ongoing and future trials of biologic therapies in lung cancer. Lung Cancer 2003;41:S175-86.